Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RESP301 in Hospitalized COVID-19 Patients
NCT04460183Phase 3Completed
- Sponsor
- Thirty Respiratory Limited
- Start
- Jul 2020
- Primary completion
- Apr 2021
- Modality
- Inhalation Devices, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of RESP301 in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Thirty Respiratory Limited. Primary endpoint: Number of Participants Who Progress by at Least One Level Higher on the Modified WHO Ordinal Scale at Day 3. Started Jul 2020; status: completed.
02
Drugs
RESP301
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04460183.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04460183.